FILANA THERAPEUTICS, INC. (FLNA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board –Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, November 11, 2026 (GLOBE NEWSWIRE) –– Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology
- Person
- Jill M. Quigley
- Title
- Independent Director
- Action
- appointed
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The appointment signals governance strengthening ahead of a pivotal trial, but no immediate financial or operational change.
Market read
Limited to FLNA shareholders; no sector‑wide catalyst.
What to watch
Potential dilution risk if new financing is needed for Phase 2a trial.
Background
Filana Therapeutics (NASDAQ: FLNA) is a biotech developing simufilam for TSC‑related epilepsy. The 8‑K reports a new independent director and upcoming Phase 2a study.
Ticker impact
Filana Therapeutics filed an 8‑K announcing the appointment of Jill M. Quigley to its board of directors and upcoming Phase 2a trial plans.
likely slight upward pressure as investors value added governance experience
New director with biotech financing background could improve execution of upcoming trial, but no immediate financial impact.
Market effects
Minor; adds credibility to a small‑cap biotech pursuing CNS trials.
Limited to US biotech investors.
Low; no broader market effect.
Counterpoint
Board change may not translate into near‑term price move; focus remains on trial data.
Key entities
- CompanyFilana Therapeutics, Inc.
NASDAQ‑listed biotech developing CNS therapies.
- PersonJill M. Quigley
New independent board member with biotech leadership experience.
